RU95109936A - Новые замещенные азетидиноны, способ их получения, фармацевтическая композиция, способ лечения - Google Patents

Новые замещенные азетидиноны, способ их получения, фармацевтическая композиция, способ лечения

Info

Publication number
RU95109936A
RU95109936A RU95109936/04A RU95109936A RU95109936A RU 95109936 A RU95109936 A RU 95109936A RU 95109936/04 A RU95109936/04 A RU 95109936/04A RU 95109936 A RU95109936 A RU 95109936A RU 95109936 A RU95109936 A RU 95109936A
Authority
RU
Russia
Prior art keywords
alkyl
azethidinones
synthesis
pharmaceutical composition
new substituted
Prior art date
Application number
RU95109936/04A
Other languages
English (en)
Other versions
RU2148056C1 (ru
Inventor
П.Дохерти Джеймс
Us]
П.Дорн Конрад
Л.Дюре Филип
Э.Финк Пол
Маккосс Мальком
Г.Миллс Сандер
К.Шах Шреник
П.Сахоо Соумиа
Дж.Хейл Джеффри
Gb]
Дж.Ланза Томас
К.Хагманн Уильям
In]
Original Assignee
Мерк Энд Ко.
Мерк Энд Ко., Инк.
Инк. (US)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Энд Ко., Мерк Энд Ко., Инк., Инк. (US) filed Critical Мерк Энд Ко.
Publication of RU95109936A publication Critical patent/RU95109936A/ru
Application granted granted Critical
Publication of RU2148056C1 publication Critical patent/RU2148056C1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Замещенные азетидиноны, имеющие общую формулу I, которые, являются мощными ингибиторами эластазы и могут использоваться как противовоспалительные и антидегенеративные агенты, при этом Rпредставляет собой (а) или (b), где Rобозначает карбокси C  -алкил, бензилокси-карбонил C  алкил или t-бутоксикарбонил C  алкил, где Q обозначает ковалентную связь или (С). У представляет собой (d) или (е) или ковалентную связь.

Claims (1)

  1. Замещенные азетидиноны, имеющие общую формулу I, которые, являются мощными ингибиторами эластазы и могут использоваться как противовоспалительные и антидегенеративные агенты, при этом R4 представляет собой (а) или (b), где Rx обозначает карбокси C1 - 6-алкил, бензилокси-карбонил C1 - 3 алкил или t-бутоксикарбонил C1 - 3 алкил, где Q обозначает ковалентную связь или (С). У представляет собой (d) или (е) или ковалентную связь.
RU95109936A 1992-10-27 1993-10-26 Замещенные азетидиноны, способ их получения, фармацевтическая композиция и способ лечения RU2148056C1 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US96680092A 1992-10-27 1992-10-27
US966,800 1992-10-27
US966.800 1992-10-27
US99183892A 1992-12-17 1992-12-17
US991,838 1992-12-17
US991.838 1992-12-17
PCT/US1993/010268 WO1994010142A1 (en) 1992-10-27 1993-10-26 New substituted azetidinones as anti-inflammatory and antidegenerative agents

Publications (2)

Publication Number Publication Date
RU95109936A true RU95109936A (ru) 1997-01-10
RU2148056C1 RU2148056C1 (ru) 2000-04-27

Family

ID=27130493

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95109936A RU2148056C1 (ru) 1992-10-27 1993-10-26 Замещенные азетидиноны, способ их получения, фармацевтическая композиция и способ лечения

Country Status (29)

Country Link
EP (1) EP0595557B1 (ru)
JP (1) JPH082868B2 (ru)
KR (1) KR950704250A (ru)
CN (1) CN1043884C (ru)
AT (1) ATE270273T1 (ru)
AU (1) AU663806B2 (ru)
CA (1) CA2108584C (ru)
CY (1) CY2529B1 (ru)
CZ (1) CZ106895A3 (ru)
DE (1) DE69333563T2 (ru)
DK (1) DK0595557T3 (ru)
DZ (1) DZ1724A1 (ru)
ES (1) ES2224095T3 (ru)
FI (1) FI951992A0 (ru)
HR (1) HRP931309A2 (ru)
HU (2) HUT72084A (ru)
IL (1) IL107321A (ru)
LV (1) LV13338B (ru)
MX (1) MX9306666A (ru)
MY (1) MY128261A (ru)
NO (1) NO305697B1 (ru)
NZ (1) NZ257755A (ru)
PL (1) PL308545A1 (ru)
PT (1) PT595557E (ru)
RU (1) RU2148056C1 (ru)
SI (1) SI9300566A (ru)
SK (1) SK53795A3 (ru)
TW (1) TW275621B (ru)
WO (1) WO1994010142A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420010A (en) * 1993-07-30 1995-05-30 Merck & Co., Inc. Assay for evaluating inhibition of polymorphonuclear leukocyte elastase by N-substituted azetidinones
WO1996029307A1 (fr) * 1995-03-23 1996-09-26 Japan Tobacco Inc. Composes de diphenylmethyle-azetidinone et inhibiteur d'elastase
US5523233A (en) * 1995-05-03 1996-06-04 Merck & Co., Inc. Enzymatic hydrolysis of 3,3-diethyl-4-[(4-carboxy)phenoxy]-2-azetidinone esters
AU701386B2 (en) * 1995-10-31 1999-01-28 Merck & Co., Inc. Process for preparing substituted azetidinones
US5808056A (en) * 1995-10-31 1998-09-15 Merck & Co., Inc. Process for preparing substituted azetidinones
WO1997021675A1 (en) * 1995-12-08 1997-06-19 Smithkline Beecham Plc Monocyclic beta-lactame derivatives for treatment of atherosclerosis
HUP9901359A3 (en) * 1996-04-26 2000-03-28 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them
EP1099690A4 (en) * 1998-07-23 2001-10-17 Shionogi & Co MONOCYCLIC BETA LACTAM COMPOUNDS AND CHYMASE INHIBITORS THAT CONTAIN THEM
RU2217196C2 (ru) * 2002-02-28 2003-11-27 Небольсин Владимир Евгеньевич Способ индукции дифференцировки клеток
FR2937972B1 (fr) * 2008-11-04 2013-03-29 Galderma Res & Dev Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
PL2407466T3 (pl) * 2009-03-09 2016-06-30 Taiho Pharmaceutical Co Ltd Związek piperazynowy zdolny do inhibitowania syntazy prostaglandyny d
FR2981933B1 (fr) * 2011-11-02 2013-11-15 Galderma Res & Dev Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ228600A (en) * 1988-04-11 1992-02-25 Merck & Co Inc 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
WO1993000332A1 (en) * 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents

Also Published As

Publication number Publication date
CA2108584C (en) 1998-11-24
PL308545A1 (en) 1995-08-21
IL107321A (en) 1998-08-16
ES2224095T3 (es) 2005-03-01
EP0595557B1 (en) 2004-06-30
HU9501184D0 (en) 1995-06-28
HU211619A9 (en) 1995-12-28
FI951992A (fi) 1995-04-26
MY128261A (en) 2007-01-31
CA2108584A1 (en) 1994-04-28
DE69333563T2 (de) 2005-08-18
MX9306666A (es) 1994-04-29
AU5028393A (en) 1994-05-12
CN1090272A (zh) 1994-08-03
DE69333563D1 (de) 2004-08-05
CY2529B1 (en) 2006-04-12
IL107321A0 (en) 1994-01-25
SI9300566A (en) 1994-09-30
HUT72084A (en) 1996-03-28
ATE270273T1 (de) 2004-07-15
NO305697B1 (no) 1999-07-12
KR950704250A (ko) 1995-11-17
CN1043884C (zh) 1999-06-30
SK53795A3 (en) 1995-09-13
RU2148056C1 (ru) 2000-04-27
NO951593L (no) 1995-06-23
HRP931309A2 (en) 1997-02-28
DZ1724A1 (fr) 2002-02-17
WO1994010142A1 (en) 1994-05-11
AU663806B2 (en) 1995-10-19
FI951992A0 (fi) 1995-04-26
PT595557E (pt) 2004-10-29
DK0595557T3 (da) 2004-10-25
NO951593D0 (no) 1995-04-26
NZ257755A (en) 1998-03-25
JPH06263723A (ja) 1994-09-20
EP0595557A1 (en) 1994-05-04
TW275621B (ru) 1996-05-11
JPH082868B2 (ja) 1996-01-17
CZ106895A3 (en) 1996-03-13
LV13338B (en) 2006-01-20

Similar Documents

Publication Publication Date Title
RU95106996A (ru) Сульфонилалканоиламино-гидроксиэтиламино-сульфонамидные соединения, фармацевтические композиции и способы лечения и ингибирования ретровирусных протеаз
RU94046149A (ru) Новые n-арил и n-гетероарил производные мочевины как ингибиторы ацил кофермента а:холестерин ацил трансферазы (асат) фармацевтическая композиция, способ ингибирования (асат)
RU94035686A (ru) 4-ариламино-бензопиран и родственные соединения, фармацевтическая композиция, способ лечения
RU94046105A (ru) АНАЛОГИ γ -АМИНОМАСЛЯНОЙ КИСЛОТЫ И L-ГЛУТАМИНОВОЙ КИСЛОТЫ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
RU95104885A (ru) 1h-индол-3-глиоксиламиды, ингибирующие spla2-медируемое выделение жирных кислот, фармацевтическая композиция
RU94045915A (ru) Производные индола, способ их получения, фармкомпозиция
RU94021350A (ru) Соединения, содержащие конденсированное бициклическое ядро, промежуточные соединения, способы их получения, фармацевтическая композиция
RU95106823A (ru) Сукциноиламиногидроксиэтиламиносульфонамиды, фармацевтическая композиция, способ ингибирования ретровирусной протеазы, способ лечения ретровирусной инфекции способ лечения спида
RU95109936A (ru) Новые замещенные азетидиноны, способ их получения, фармацевтическая композиция, способ лечения
CA2171637A1 (en) Substituted Azaheterocyclecarboxylic Acids
LU91145I2 (fr) FIROCOXIB facultativement sous forme d'un sel pharmaceutiquement acceptable (PREVICOX).
DE69830504D1 (de) Antithrombotische mitteln
FI882176A0 (fi) Menetelmä terapeuttisesti aktiivisten heterosyklisten peptidien valmistamiseksi ja niiden valmistuksessa käyttökelpoisia välituotteita
RU94040859A (ru) Аминопроизводные оксо- и гидрокси-замещенных углеводородов, способы получения, фармацевтические композиции, способ ингибирования ретровирусной протеазы, способ лечения спида у млекопитающих
RU94043324A (ru) Гетеробициклические соединения
RU94043645A (ru) Способ получения производных 3-хиннолонкарбоновой кислоты
RU94028888A (ru) Производные 1,3-замещенного циклоалкана и циклоалкена, смесь их изомеров или индивидуальные изомеры, их гидраты и соли, способ их получения и фармацевтическая композиция
RU94038256A (ru) Производные пиразолопиримидина, способ их получения, фармацевтические композиции на их основе
RU94022277A (ru) Новые 19-норстероиды, имеющие в положении 11 - бета феноксиалкилсульфонамидную или феноксиалкилсульфонилкарбамидную цепь, метод и промежуточные продукты их получения, и содержащая их фармацевтическая композиция
Somfai et al. A potential carbapenem intermediate from L-glutamic acid
RU94046270A (ru) Лактамовые дипептиды, обладающие ингибирующей активностью по отношению к эластазе лейкоцитов человека, способ получения, фармацевтическая композиция
RU95104939A (ru) Тетрациклические соединения, способ их получения и промежуточные соединения для этого и применение их в качестве противоопухолевых веществ
RU94046387A (ru) Производные пиримидина, способ их получения, фармацевтическая композиция, ее применение и промежуточные продукты
RU95107655A (ru) Глюкопиранозидбензотиофены, способ получения, фармацевтическая композиция
RU94046012A (ru) Способ стереоспецифического гидролиза производных пиперидиндиона, продукт гидролиза и способ получения пароксетина